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Summary
We have identified and sequenced a cDNA that encodes
an apparent human orthologue of a yeast protein-X
component (ScPDX1) of pyruvate dehydrogenase mul-
tienzyme complexes. The new human cDNA that has
been referred to as “HsPDX1” cDNA was cloned by use
of the “database cloning” strategy and had a 1,506-bp
open reading frame. The amino acid sequence of the
protein encoded by the cDNA was 20% identi-
cal with that encoded by the yeast PDX1 gene and
40% identical with that encoded by the lipoate ace-
tyltransferase component of the pyruvate dehy-
drogenase and included a lipoyl-bearing domain that is
conserved in some dehydrogenase enzyme complexes.
Northern blot analysis demonstrated that the major
HsPDX1mRNAwas 2.5 kb in length and was expressed
mainly in human skeletal and cardiac muscles but was
also present, at low levels, in other tissues. FISH analy-
sis performed with a P1-derived artifical chromosome
(PAC)–containing HsPDX1 gene sublocalized the gene
to 11p1.3. Molecular investigation of PDX1 deficiency
in four patients with neonatal lactic acidemias revealed
mutations 78del85 and 965del59 in a homozygous state,
and one other patient had no PDX1 mRNA expression.
Introduction
The mammalian and yeast pyruvate dehydrogenase
multienzyme complexes (PDHc) contain a tightly asso-
ciated 50,000-kD polypeptide of unknown func-
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tion—component X (PDX1)—in addition to its three
constituent enzymes, pyruvate dehydrogenase (E1; E.C.
1.2.4.1), lipoate acetyltransferase (E2; E.C. 2.3.1.12),
and lipoamide dehydrogenase (E3; E.C. 1.6.4.3), which
are jointly responsible for production of acetyl-CoA and
reduced nicotinamide adenine dinucleotide (Reed 1974;
De Marcucci and Lindsay 1985; Jilka et al. 1986). It has
been shown elsewhere that component X is an immu-
nologically distinct entity (De Marcucci and Lindsay
1985; Jilka et al. 1986; Rahmatullah et al. 1989b) that
is related to the E2 subunit, particularly in its N-terminal
region; moreover, bovine component X resembles bovine
E2 in that both proteins contain a lipoyl moiety that
undergoes reductive acetylation and deacetylation (De
Marcucci et al. 1986; Hodgson et al. 1986; Jilka et al.
1986; Rahmatullah and Roche 1987). There is also some
sequence similarity in the amino-terminal segment of
component X and E2 (Niu et al. 1988; Rahmatullah et
al. 1989a). The role of component X has not yet been
clearly demonstrated. Its primary role appears to be a
structural one in mediating the binding and optimal ori-
entation of E3 with regard to the E2 core assembly (Nea-
gle and Lindsay 1991) interaction required for optimal
catalytic efficiency of the complex (Powers-Greenwood
et al. 1989). The importance of component X is high-
lighted by the severe consequences of its deficiency in
humans. This autosomal recessive disorder manifests
with a complex organic acidosis, a result of the accu-
mulation of the a-keto acid substrates, and with varying
degrees of neurological dysfunction that often result in
death within the first few years of life (Robinson et al.
1990; Marsac et al. 1993; Geoffroy et al. 1996). The
residual level of PDHc activity observed in deficient fi-
broblasts is !20% of normal. In accordance with pre-
vious in vitro studies of reconstituted mammalian PDHc
when the component-X subunit has been selectively de-
graded by proteolysis (Sanderson et al. 1996), the im-
munoblotting studies, performed with antibodies against
PDHc, clearly have demonstrated the absence of com-
ponent X in some patients. The other components ap-
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pear normal, compared with those control samples. In
addition, SSCP analysis and sequencing of the whole
coding region excludes the involvement of an X-linked
PDH-E1a gene abnormality as an explanation of the low
PDHc activity. Moreover, the fact that PDHc activities
are normal in the mother and the father, with a normal
component X on western immunoblot analysis, strongly
suggests that these are primary defects in these families.
We report here the identification of the human cDNA
sequence for the X-lipoyl–containing component of the
PDHc, its tissue-specific expression, and the chromo-
somal localization of its gene. Examination of four pa-
tients presenting with the neonatal form of lactic acidosis
revealed three mutations and two frameshift deletions,
and one patient had no detectable HsPDX1 transcript.
Subjects and Methods
Subjects
Patient S.D., diagnosed with a neonatal lactic acide-
mia, was a female newborn born from unrelated healthy
nonconsanguineous parents after a normal pregnancy
and delivery. A case report detailing the clinical course
and biochemical investigation of this patient and her
family has been described elsewhere (Geoffroy et al.
1996). The patient is under a physician-supervised reg-
imen of a low-glucose, ketogenic diet, which has dra-
matically improved metabolic status, and she is presently
doing well at 1 year of age. Patients R.D. and R.H. were
brothers; the parents, of Portuguese origin, were first
cousins. The brothers presented with encephalomyelopa-
thy and chronic lactic acidemia and had a normal E1
subunit of PDHc but deficiency of PDX1 protein. Both
patients went into a deep coma with irreversible severe
lactic acidosis and died of cardiopulmonary arrest. These
cases are described in the report by Marsac et al. (1993).
The fourth case of neonatal lactic acidemia with a PDHc
defect caused by the specific absence of component X is
patient K.M., who was born after an uneventful preg-
nancy, from healthy nonconsanguineous parents. He
was dysmorphic, with trigonocephaly, a frontal metopic
ridge, and a supranasal lipoma. He was developmentally
delayed from birth. He became severely quadriplegic and
microcephalic. At the age of 10 mo high levels of serum
lactate and pyruvate were found. A computed-tomog-
raphy scan of the brain revealed a partial frontal corpus
callosum agenesis with dilated lateral ventricles. The full
case report has been published by De Meirleir et al. (in
press).
Database Searches
Homology searches for various expressed sequence
tags (ESTs) were performed on data from the DNA Da-
tabase of Japan (http://www.nig.ac.jp/home.html), the
National Center for Biotechnology Information (http://
www.ncbi.nlm.nih.gov/), and the European Molecular
Biology Laboratories (EMBL) (http://www.ebi.ac.uk/);
and comparative genomics and genome cross-referenc-
ing were performed on data from XREFdb (http://
www.ncbi.nlm.nih.gov/XREFdb/) and on a database
of precalculated comparison (http://protein.toulouse
.inra.fr/.html).
cDNA Cloning and Sequence Analysis
We obtained I.M.A.G.E. Consortium cDNA clones,
corresponding to human ESTs H58032 and AA159537,
from Genome Systems. The composite human sequence
derived from sequencing these EST clones extended from
bp 1 (where 1 is the A of the initiation methionine)
to the start of the poly(A) tail (bp1744). TheHsPDX1
cDNA sequence (Y13145) that we deposited into EMBL
is a full-length fetal liver/spleen 1NFLS clone (bp 1 to
bp 1611) identical to one derived from an adult pan-
creatic-tissue clone. Verification of the 5′ end (bp 1 to
bp151) was obtained by 5′-RACE (rapid amplification
of cDNA ends) analysis using the human Pancreas Mar-
athon-Ready cDNA (Clontech-Ozyme, France) and ac-
cording to the manufacturer’s cDNA-amplification pro-
tocol. Sequencing was performed with the AutoRead
DNA Sequencing Kit (Pharmacia Biotech), which uses
T7 DNA polymerase and an A.L.F. automated DNA
sequencer (Pharmacia Biotech). The cDNA clones were
sequenced completely, in both directions. Probe labeling
was performed by use of random hexamers or gene-
specific primers as described elsewhere (Feinberg and
Vogelstein 1983).
RNA Isolation, Northern Blot Analysis, and
Chromosome Mapping
We isolated total RNA from cultured skin fibroblasts,
either by guanidium thiocyanate extraction (Chirgwin
et al. 1979) or with Trizol reagent (Life Technolo-
gies–BRL). Chromosomal assignment of the HsPDX1
was performed by use of in situ hybridization as de-
scribed elsewhere (Liu et al. 1986). Probe labeling was
performed by use of random hexamers or gene-specific
primers as described elsewhere (Feinberg and Vogelstein
1983). Standard procedures were used for P1-derived
artificial chromosome (PAC) library screening (Sam-
brook et al. 1989). PAC DNAs were prepared according
to the method of Wang et al. (1994). H58032 cDNA
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(bp 1 to bp  1744) was used to probe the nor-
thern blots (Clontech-Ozyme); poly(A) binding protein
(PABP) and lipoate acetyltransferase component (i.e.,
E2) cDNAs were controls.
Western Blot Analysis
Fibroblast or b-lymphoblastoid–cell line mitochondria
(5 mg) were subjected to 10% SDS-PAGE under reducing
conditions. Proteins were electrotransferred onto nitro-
cellulose membranes at 100 V for 2 h in 25 mM Tris
and 192 mM glycine buffer pH 8.3. Membranes were
incubated for 1 h in PBS containing 2% nonfat dry milk,
1% ethanolamine, and 0.02% thimerosal; were washed
in PBS and 0.1% Tween-20; and incubated overnight at
4C with rabbit anti-PDHc antibody (1/2,000 dilution)
diluted in PBS, 1% BSA, 0.05% Tween-20, and 0.02%
thimerosal. After an extensive washing, membranes were
incubated for 1 h at room temperature with horseradish
peroxidase–conjugated goat anti-rabbit immunoglobu-
lin G (1/3,000). Immunocomplexes were detected by the
Amersham ECL detection reagents.
Reverse Transcriptase–PCR (RT-PCR) Analysis
RT-PCR was performed by use of the Superscript
RT protocol (Life Technologies–BRL), 50 ng primer
XR2 (located in the 3′ UTR), and 3 mg total fibroblast
RNA. A 1–3-ml portion of the first-strand cDNA was
amplified with primers F2/DW2 and UP2/XR (described
below). The RNA isolated from each cell line was reverse
transcribed, amplified, and sequenced a minimum of
three times, to insure the authenticity of mutations found
on the sequencing of amplified transcripts. The PCR
products were gel purified and sequenced directly by use
of a Sequitherm sequencing kit (Epicentre Technolo-
gies–TEBU). Unless otherwise specified, PCR reactions
contained 75 ng template DNA, 10 pmol each primer,
200 mM each dNTP, 0.25 U Taq DNA polymerase, and
buffer (1.5 mM MgCl2; Life Technologies)1 # PCR
in 50 ml. Standard cycling conditions were used (Aral et
al. 1996).
GenBank Accession Numbers
GenBank accession numbers are as follows: human
ESTs—H58032, AA159537, and T16961; HsPDX1
cDNA—Y13145; ScPDX1—M28222; and PDC-
E2—Y00978 and X13969.
Results
“Database Cloning” of HsPDX1 cDNA
The yeast Saccharomyces cerevisiae component X,
ScPDX1, has been cloned and sequenced elsewhere (Be-
hal et al. 1989). Furthermore, study of the ScPDX1 gene
has demonstrated that its disruption results in the dis-
sociation of the E3 component from the mutant com-
plex, concomitant with a loss of pyruvate-oxidation ca-
pacity (Lawson et al. 1991). Deletion analysis also has
shown that the putative subunit-binding domain (resi-
dues 144–180) plays an important role in the binding
of E3 (Lawson et al. 1991). To identify the molecular
basis of PDHc deficiency with a missing component X,
we used XREFdb (Bassett et al. 1995, 1997) to probe
the database of ESTs by use of the S. cerevisiae PDX1
protein sequence. Initially, we identified three overlap-
ping human partial-length candidate cDNAs (GenBank
accession numbers H58032, AA159537, and T16961,
from fetal liver/spleen, pancreas, and infant-brain li-
braries, respectively), with P values of 1.28, 4.28, and
1.810, respectively. The composite sequence had a P
value of 1.024 and contained an open reading frame
(ORF) that we estimated to be ∼100% of the full length,
on the basis of comparison to both ScPDX1 and the
human lipoate acetyltransferase (PDC-E2) cDNA. From
the 2.5-kb HsPDX1 cDNA (GenBank accession number
Y13145), we sequenced 1,744 bp and found no 5′ UTR
sequence, a 238-bp 3′ UTR, and a 1,506-bp ORF en-
coding a 501-amino-acid protein (fig. 1). The initiation
methionine cannot be predicted Kozak (1992), because
of quasi-absent 5′ UTR sequence in all sequenced cDNA
clones (clones 205084 and 591560). Therefore, using
the EST sequence information (H58032 and AA159537,
respectively) from these clones, we set out to clone the
5′ end of the full-length HsPDX1 cDNA, by use of the
5′ RACE (Frohman et al. 1988; Frohman 1993) strategy,
from a pancreas Marathon-Ready (Clontech-Ozyme)
cDNA library (Chenchik et al. 1995). We were able to
amplify a unique cDNA fragment by use of the two gene-
specific primers (1R and 2R), on the one hand, and 5′
adaptor-specific primers, provided with the library, on
the other hand (data not shown). PCR-amplified 5′-end
cDNA fragments were subjected to direct cycle sequenc-
ing by the primer-walking strategy, from the known se-
quences at the 3′ end of the cDNA toward the unknown
sequences at the 5′ end of the cDNA. The sequence data
from the 5′-RACE fragment gave no additional sequence
information for the 5′ UTR. Since PDX1 is a mitochon-
drial protein, it must undergo a proteolytic removal of
its mitochondrial leader peptide. According to Hendrick
et al. (1989), a highly conserved 3-amino-acid motif is
common to this class of leader peptides. This motif in-
cludes an arginine at position 10, a hydrophobic res-
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Figure 1 Comparison of amino acid sequence (single-letter code) of HsPDX1 with that of PDC-E2 (A) and with that of ScPDX1 (B).
The deduced sequences of HsPDX1, PDC-E2, and ScPDX1 are aligned for maximum similarities, by the sequence-alignment tool Clustal V.
Identical amino acids are indicated by an asterisk (*); and similar amino acids are indicated by periods (.). The arrowhead indicates the putative
cleavage site of the HsPDX1 leader peptide. Both the lipoyllysine residue in the lipoyl domain and the residues in the putative active site of
PDC-E2 are denoted by black dots. The lipoyl domains (amino-terminal), E3-binding domains, and catalytic inner-core domains (carboxy-
terminal) are denoted by unbroken lines.
idue at position 8, and serine, threonine, or glycine at
position 5, relative to the mature amino terminus. Us-
ing this criteria, we hypothesized that the putative cleav-
age site of the PDX1’s leader peptide, by matrix-pro-
cessing protease, must occur between residues at 53 and
54, such that arginine at position 10, threonine at po-
sition 5, and phenylalanine, a hydrophobic residue, at
position 8 may account for the conserved 3-amino-
acid motif. The presequence is rich in basic and hy-
droxylated amino acid residues and is devoid of acidic
amino acid residues. This feature, similar to the putative
presequence of PDC-E2 (Thekkumkara et al. 1988), is
characteristic of presequences of mitochondrial-matrix/
inner-membrane proteins (Von Heijne 1986). Compar-
ison of the deduced amino acid sequences of human
PDX1 (HsPDX1) and experimentally (partially se-
quenced) determined N-terminal amino acid sequences
of bovine heart PDX1 (Rice et al. 1992), reveals 100%
sequence identity. Comparison of the deduced amino
acid sequences of HsPDX1 and PDC-E2 reveals that
both the amino-terminal part (residues 55–131) and the
carboxyl-terminal part, including catalytic inner-core
domains (residues 258–501) of HsPDX1 resemble E2
(fig. 1A). The two proteins exhibit 50% sequence iden-
tity in the amino-terminal segment that corresponds to
the putative lipoyl-bearing domain of E2 (residues
77–111). This extensive homology indicates that
HsPDX1 and PDC-E2 evolved from a common ancestor.
In contrast to PDC-E2, ScPDX1 and HsPDX1 share se-
quence identity only in the lipoyl-bearing domain (fig.
1B). The overall amino acid identity between HsPDX1
and PDC-E2 is 40%, and that between HsPDX1 and
ScPDX1 is 20%.
Secondary-Structure Predictions of HsPDX1 Protein
In addition to “live” on-line homology searching, we
probed precalculated databases with the primary amino
acid sequence of the HsPDX1. We obtained multiple
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Figure 2 FISH to human metaphase chromosomes with the PAC
clone F1172, containing the human gene for PDX1.The human gene
encoding PDX1 is assigned to human chromosome 11p1.3.
Figure 3 Western blotting of cultured skin fibroblast mitochon-
dria with anti–PDH complex antibodies. Mitochondria (≈5 mg protein)
from each cell line were solubilized in sample buffer and were resolved
on a 10% SDS–polyacrylamide gel, under reducing conditions. The
proteins were then electroblotted onto a nitrocellulose support matrix
and were probed with antibodies that reacted with all subunits of the
purified PDHc, except for the E3 subunit, which is poorly immuno-
genic. Immunoreactive proteins were visualized by electrogenerated
chemiluminescence-detection reagents. Lane 1, Control cell lines. Lane
2, Patient S.D. Lane 3, Patient K.M. Lane 4, Patient R.D.
alignments with consensus sequences derived for two
protein domains (data not shown). The first domain of
homology on the HsPDX1 lies between residues 77 and
111 in the N-terminal moiety, and it is shared among
three proteins—namely, the dihydrolipoamide acetyl-
transferase component (i.e., E2) of the pyruvate dehy-
drogenase complex, the dihydrolipoamide succinyltrans-
ferase component (i.e., E2) of the 2-oxoglutarate
dehydrogenase complex precursor (E2K; E.C. 2.3.1.61),
and the biotin carboxyl–carrier protein of acetyl-CoA
carboxylase (BCCP; E.C. 6.4.1.2). This domain bears
two highly conserved amino acid residues, K97 and G108,
and corresponds perfectly to the putative lipoyl-bearing
domain. The second domain of homology lies between
the amino acid residues 258 and 501 in the HsPDX1 C-
terminal moiety that contains the highly conserved se-
quence D-H-R-X-X-D-G, which is thought to be part of
the putative catalytic site of all dihydrolipoamide ace-
tyltransferases and succinyltransferases, such as the li-
poamide acetyltransferase component (i.e., E2) precur-
sor of the branched-chain a-keto acid dehydrogenase
complex (BCKAD E2 subunit; E.C. 2.3.1.–), the dihy-
drolipoamide acetyltransferase component (i.e., E2) of
the pyruvate dehydrogenase complex (E.C. 2.3.1.12),
and the dihydrolipoamide succinyltransferase compo-
nent (i.e., E2) of the 2-oxoglutarate dehydrogenase com-
plex precursor (E2K; E.C. 2.3.1.61). The HsPDX1 has,
instead, the D474-S-R-X-X-D-D480 motif, which suggests
that HsPDX1, as its yeast orthologue, in contrast to
PDC-E2, is not able to catalyze an acetyl transfer be-
tween the protein-bound S-acetyldihydrolipoyl moiety
and coenzyme A. But this assertion has yet to be deter-
mined experimentally. It should also be noted that, like
its yeast orthologue, HsPDX1 protein does contain an
E3-binding domain (fig. 1A, residues ≈326–361 of PDC-
E2), as in any other a-keto acid dehydrogenase com-
plexes, in which E3 binds directly to the E2 core.
Tissue-Specific Expression Pattern of HsPDX1 mRNA
Because mitochondria are present in virtually all mam-
malian cells, we utilized a multitissue northern blot as
an initial test of the tissue-expression pattern of a pre-
sumed PDX1 gene. As expected for a gene involved in
the intermediary metabolism of a ubiquitous organelle,
an HsPDX1 cDNA probe detects a transcript (≈2.5 kb)
in all tissues examined, in a very low abundance (data
not shown). Tissues with the highest expression are skel-
etal muscle and heart.
Chromosomal Localization of the HsPDX1 Gene
We next attempted to determine the chromosomal lo-
calization of the gene that encodes the HsPDX1. As a
first step, we used a 535-bp PCR probe from the
HsPDX1 cDNA in order to screen and isolate human
PAC clones containing the human gene encoding
HsPDX1, from a whole-genome PAC library spotted on
high-density filters (Lehrach et al. 1990). We isolated
five positive clones (LLNLP704C05279Q13, LLNLP-
704F1172Q13, LLNLP704L10149Q13, LLNLP704-
L10167Q13, and LLNLP704G24136Q13). Two of
these five clones, F1172 and G24136, were used to pre-
pare PAC DNA probes for FISH to metaphase chro-
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Figure 4 Identification of mutations in the HsPDX1 mRNA transcripts in PDH-deficient patients. A, top, Northern blot of total RNA
(20 mg total RNA/lane) from controls’ and patients’ fibroblasts probed with [32P]-HsPDX1 cDNA. A 2.5-kb PDX1 transcript is present in six
of the seven lanes, which show results for control b-lymphoblastoid cell lines (lanes 1 and 2) and for fibroblast cell lines (lane 3, patient K.M.’s
mother; lane 5, patient S.D.; and lanes 6 and 7, controls); the exception was patient K.M. (lane 4), whose PDX1 mRNA was undetectable. A,
bottom, Same blot, probed with a PABP cDNA probe to control for the quality and quantity of the RNA. B, Detection of deleted RT-
PCR–amplified cDNA fragments F2/DW2 by agarose gel electrophoresis. RT-PCR (using primers F2 and DW2; for the primer sequences, see
the text) was used to amplify a 793-nt-long cDNA fragment (between bp 37 and bp 828) from two unaffected individuals (lanes 2 and 5),
a 708-nt-long cDNA fragment from patient S.D. (lane 4), and, in a heterozygous state, both a 793-nt-long fragment and a 708-nt-long cDNA
fragment from patient S.D.’s mother (lane 3). Standards of known size also were run (lanes 1 and 6). C, Detection of abnormal RT-PCR–amplified
cDNA fragments UP2/XR by agarose gel electrophoresis. RT-PCR (using primers UP2 and XR; for the primer sequences, see the text) was used
to amplify a 554-nt-long cDNA fragment (between bp 808 and bp 1362) from two unaffected individuals (lanes 2 and 4) and a 495-nt-
long cDNA fragment from patient R.D. (lane 3). Standards of known size also were run (lanes 1 and 5). D, Schematic representation of HsPDX1
cDNA, along with the primers’ positions for RT-PCR amplifications.
mosomes from a healthy male. Under these experimental
conditions, a specific signal appearing as symmetrical
spots on both chromatids of chromosome 11p1.3 was
obtained in 190% of the 50 metaphases examined (fig.
2), with both F1172 and G24136.
HsPDX1-Gene Mutation Analysis
We confirmed the functional impairment of the
HsPDX1 in two unrelated patients and two male sib-
lings, by immunoblotting studies (fig. 3) performed with
antibodies against PDHc components, which clearly
demonstrated the absence of component X. This result
also implicated HsPDX1 as the gene responsible for the
clinical and biochemical signs of lactic acidemia in a
preliminary molecular investigation of these deficiencies.
For the mutation analysis of HsPDX1 in a series of two
unrelated patients and in two male siblings with neonatal
lactic acidemias, we first determined, by northern blot
analysis, the expression levels of HsPDX1 mRNA in
patients’ fibroblasts probed with a complete HsPDX1
cDNA probe. The size and amount of HsPDX1 mRNA
in patient cells was similar to that of the controls when
sample loading differences were accounted for, except
for patient K.M., who has little if any detectable tran-
script, suggesting a transcriptional regulation abnor-
mality (fig. 4A). Also, this reduction supports the pre-
diction of involvement of PDX1 in neonatal lactic
acidemia and predicts heterogeneity in the responsible
mutations. We then utilized RT-PCR to amplify
HsPDX1 cDNA from fibroblast RNA isolated from
patients’ fibroblasts, by using, for the first half of the
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cDNA (cDNA fragment F2/DW2), primers F2 (sense, 5′-
CTGCTGCGTTATCTTGTGGGC T-3′) and DW2 (an-
tisense, 5′-TCAGTGAATGTGCCCACTGCATTG-3′),
which amplify a 793-bp fragment (bp 37 to bp 828)
and, for the second half of the cDNA (cDNA fragment
UP2/XR), UP2 (sense, 5′-CAATGCAGTGGGCACATT-
CACTGA-3′) and XR (antisense, 5′-CCTCTTCATCCT-
CAGTGAGCTTCA-3′), which amplify a 554-bp frag-
ment (bp 808 to bp 1362); the total length of the
amplified cDNA includes ∼90% of the ORF (fig. 4D).
First, we found that the yield of RT-PCR product am-
plified from the fibroblasts belonging to patient K.M.
was reduced compared with that in control fibroblasts,
although the starting amounts of total RNA material
were equalized in all individuals (data not shown).
Moreover, the HsPDX1 cDNA fragments amplified
from the cells of patient S.D. and of the two male siblings
R.D. and R.H were decreased in size, compared with
those in controls. We sequenced the products directly
and found that patient K.M. had a normal cDNA se-
quence, whereas patient S.D. was homozygous for an
85-bp deletion between bp 77 and bp 162, produc-
ing the 78del85 mutation (data not shown); patient
S.D.’s mother was heterozygous for this mutation (fig.
4B). In the two male siblings, R.D. and R.H., the size
of the amplified cDNA fragment was also decreased
compared with that in controls (fig. 4C). Direct sequenc-
ing of this cDNA revealed a 59-nt deletion between bp
964 and bp 1024, producing a 965del59 mutation
(data not shown). Neither the 85-bp-deletion allele nor
the 965del59 allele was detected in the 30 controls.
Discussion
Evolutionary conservation of the enzymes belonging
to the various metabolic pathways, together with exten-
sive molecular studies of the mutant variants in yeast
and the rapidly expanding database of expressed mam-
malian genes, provides the resources necessary to iden-
tify the human orthologues of these enzymes’ genes (Bas-
sett et al. 1995, 1997). Strategies based on these
resources have already proved successful (Bronner et al.
1994; Fishel et al. 1994; Aral et al. 1996; Dodt et al.
1996). In the present study, we utilized a “database clon-
ing” strategy with ScPDX1 to identify orthologous hu-
man cDNAs. The HsPDX1 gene has been localized to
human chromosome 11p1.3 by in situ hybridization; the
PDC-E2 gene has also been localized to human chro-
mosome 11 (Genome Database accession number
750238). So, from a molecular-evolutionary point of
view, it may be of interest that two components of the
same enzyme complex, having strong similarities in their
amino acid sequences, are on the same chromosome.
Secondary-structure predictions for HsPDX1 protein
clearly demonstrated its role in maintaining the three-
dimensional structure of the PDHc, by predicting the
correct association of E3 to E2 as a core assembly; these
interactions between E2 and PDX1 and E3 are required
for an optimal catalytic efficiency of the complex. We
identified two major deleterious pdx1 mutant al-
leles—namely, 78del85 and 965del59—and one other
patient had a severely reduced level of HsPDX1 mRNA.
The 78del85 causes an 85-nt deletion starting with nu-
cleotide 78 in cDNA, leading to a frameshift on trans-
lation and predicting production of a truncated PDHX1
of 25 amino acids, lacking the remaining 476 amino
acids. The 965del59 causes a 59-nt deletion starting with
nucleotide 965 in cDNA, leading to a frameshift on
translation and predicting production of a truncated
PDHX1 of 321 amino acids, lacking the remaining 180
amino acids. Further in vitro expression studies will be
necessary to confirm the impact of 78del85 and
965del59 on the function of HsPDX1 inside the PDHc.
Futhermore, we have not completed a comprehensive
survey of the HsPDX1-gene mutations and expect to
find more mutations in our cohort of 30 patients who
have documented neonatal lactic acidemia and who, on
the basis of immunoblot analysis, have PDHc deficiency
with a normal E1a along with normal size and amount
of HsPDX1. For example, the mutation(s) responsible
for the severe reduction of HsPDX1 mRNA in patient
K.M. is unknown. The identification of HsPDX1 as the
gene deficient in neonatal lactic acidemia in one group
of PDHc-deficient patients allows prenatal diagnosis and
carrier detection in at-risk families. Furthermore, this
approach shows, once more, the power, in the search
for human disease genes, of the combined efforts re-
sulting from the various investigations that are as diverse
as the clinical biochemistry, yeast genetics, and homol-
ogy screening of the continuously expanding databases
of ESTs.
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